ANTI-N3PGLU AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF

The invention is directed to a short term induction treatment with anti-N3pGlu Aß antibodies of a disease characterized by deposition of Aß in the brain, that include Alzheimer's disease (AD), Down's syndrome, and cerebral amyloid angiopathy (CAA). In certain embodiments, patients are admi...

Full description

Saved in:
Bibliographic Details
Main Authors DEMATTOS, RONALD BRADLEY, IRIZARRY, MICHAEL CARL
Format Patent
LanguageEnglish
French
Published 22.08.2023
Subjects
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The invention is directed to a short term induction treatment with anti-N3pGlu Aß antibodies of a disease characterized by deposition of Aß in the brain, that include Alzheimer's disease (AD), Down's syndrome, and cerebral amyloid angiopathy (CAA). In certain embodiments, patients are administered an induction dose of 10 to 60 mg/kg of an anti-N3pGlu Aß antibody for a period of 6 months or less. L'invention concerne un traitement par induction à court terme avec des anticorps anti-N3pGlu Aß d'une maladie caractérisée par le dépôt de Aß dans la tête, qui inclus la maladie d'Alzheimer (AD), le syndrome de Down et l'angiopathie amyloïde cérébrale (CAA). Dans certains modes d'emploi, une dose d'induction de 10 à 60 mg/kg d'un anticorps anti-N3pGlu Aß est administrée à des patients pendant une période inférieure ou égale à 6 mois.
Bibliography:Application Number: CA20173029550